Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Effexor_XR
|
| gptkbp:activities |
gptkb:drug
|
| gptkbp:approves |
gptkb:1993
gptkb:FDA |
| gptkbp:brand |
gptkb:Effexor
gptkb:Effexor_XR |
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
antidepressants
serotonin-norepinephrine reuptake inhibitors |
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
MAO inhibitors
severe renal impairment hypersensitivity to venlafaxine |
| gptkbp:dosage_form |
75 mg to 375 mg daily
|
| gptkbp:form |
gptkb:tablet
extended-release capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
venlafaxine
|
| gptkbp:ingredients |
C17 H19 N O2
venlafaxine hydrochloride |
| gptkbp:interacts_with |
gptkb:beer
antihypertensives other antidepressants |
| gptkbp:is_atype_of |
N06 A X16
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
social anxiety disorder
generalized anxiety disorder major depressive disorder panic disorder |
| gptkbp:lifespan |
5 hours
11 hours (extended-release) |
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
gptkb:historical_event
anxiety disorders social anxiety disorder neuropathic pain panic disorders |
| gptkbp:side_effect |
dizziness
nausea insomnia constipation dry mouth increased blood pressure |
| gptkbp:symptoms |
dizziness
fatigue headache nausea irritability |
| gptkbp:type_of |
93413-69-5
|